Canada Pension Plan Investment Board bought a new position in Bioverativ Inc (NASDAQ:BIVV) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,400 shares of the biotechnology company’s stock, valued at approximately $194,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BIVV. First Trust Advisors LP bought a new position in shares of Bioverativ in the third quarter valued at $38,238,000. First Quadrant L P CA bought a new position in shares of Bioverativ in the third quarter valued at $19,310,000. Peregrine Capital Management LLC bought a new position in shares of Bioverativ in the third quarter valued at $17,643,000. Nationwide Fund Advisors bought a new position in shares of Bioverativ in the third quarter valued at $17,617,000. Finally, New York State Teachers Retirement System bought a new position in shares of Bioverativ in the third quarter valued at $11,348,000. Hedge funds and other institutional investors own 96.95% of the company’s stock.

Several research analysts have issued reports on the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $70.00 price target (up previously from $67.00) on shares of Bioverativ in a report on Wednesday, August 9th. Cowen and Company reaffirmed a “buy” rating and issued a $80.00 price target on shares of Bioverativ in a report on Friday, August 4th. Zacks Investment Research raised Bioverativ from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Deutsche Bank AG set a $53.00 price target on Bioverativ and gave the company a “hold” rating in a report on Monday. Finally, Argus raised Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target on the stock in a report on Wednesday, September 20th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $60.93.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/canada-pension-plan-investment-board-invests-194000-in-bioverativ-inc-bivv-stock/1721273.html.

Shares of Bioverativ Inc (BIVV) opened at $50.24 on Thursday. Bioverativ Inc has a one year low of $40.00 and a one year high of $64.41.

Bioverativ (NASDAQ:BIVV) last announced its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The company had revenue of $291.60 million for the quarter, compared to the consensus estimate of $285.45 million. Bioverativ’s revenue for the quarter was up 27.2% on a year-over-year basis. equities analysts forecast that Bioverativ Inc will post 2.45 earnings per share for the current year.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Institutional Ownership by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.